Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Shares Issued (2019 - 2025)

Historic Shares Issued for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $257000.0.

  • Allogene Therapeutics' Shares Issued fell 6215.02% to $257000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $895000.0, marking a year-over-year decrease of 4169.38%. This contributed to the annual value of $1.5 million for FY2024, which is 3850.16% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Shares Issued is $257000.0, which was down 6215.02% from -$9.4 million recorded in Q2 2025.
  • Allogene Therapeutics' Shares Issued's 5-year high stood at $10.0 million during Q1 2025, with a 5-year trough of -$9.4 million in Q2 2025.
  • Moreover, its 5-year median value for Shares Issued was $810500.0 (2023), whereas its average is $1.1 million.
  • In the last 5 years, Allogene Therapeutics' Shares Issued plummeted by 10003.11% in 2022 and then skyrocketed by 106845.79% in 2025.
  • Allogene Therapeutics' Shares Issued (Quarter) stood at $322000.0 in 2021, then skyrocketed by 189.13% to $931000.0 in 2022, then fell by 17.83% to $765000.0 in 2023, then decreased by 11.24% to $679000.0 in 2024, then crashed by 62.15% to $257000.0 in 2025.
  • Its Shares Issued stands at $257000.0 for Q3 2025, versus -$9.4 million for Q2 2025 and $10.0 million for Q1 2025.